Brian M. Stuglik net worth and biography

Brian Stuglik Biography and Net Worth

Director of Puma Biotechnology

Mr. Stuglik was appointed as a director and as a member of the Commercial Committee of Puma Biotechnology on July 5, 2020. He served as Chief Executive Officer of Verastem, Inc. from July 2019 through July 2023 and has served as a member of its Board of Directors since September 2017. He has also served as a member of the Board of Directors of Oncopeptides AB since May 2018.

Mr. Stuglik founded Proventus Health Solutions in January 2016 and has over three decades of experience in U.S. and international pharmaceutical development, product strategy, and commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from 2009 to December 2015.

Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research, and the International Association for the Study of Lung Cancer. Mr. Stuglik was selected as a director because of his significant experience and background in the life sciences industry and, in particular, commercialization of pharmaceutical therapies.

What is Brian M. Stuglik's net worth?: The estimated net worth of Brian M. Stuglik is at least $762.65 thousand as of December 16th, 2025. Stuglik owns 101,147 shares of Puma Biotechnology stock worth more than $762,648 as of April 28th. This net worth evaluation does not reflect any other assets that Stuglik may own. Learn More about Brian M. Stuglik's net worth.
How do I contact Brian M. Stuglik?: The corporate mailing address for Stuglik and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Brian M. Stuglik's contact information.
Has Brian M. Stuglik been buying or selling shares of Puma Biotechnology?: Brian M. Stuglik has not been actively trading shares of Puma Biotechnology during the last quarter. Most recently, Brian M. Stuglik sold 8,100 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.39, for a transaction totalling $27,459.00. Following the completion of the sale, the director now directly owns 94,958 shares of the company's stock, valued at $321,907.62. Learn More on Brian M. Stuglik's trading history.
Who are Puma Biotechnology's active insiders?: Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?: During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company. Learn More about insider trades at Puma Biotechnology.
Information on this page was last updated on 1/7/2026.

Brian M. Stuglik Insider Trading History at Puma Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/13/2025	Sell	8,100	$3.39	$27,459.00	94,958

Brian M. Stuglik Buying and Selling Activity at Puma Biotechnology

Puma Biotechnology Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Today's Range

Now: $7.54

$7.50

$7.73

50 Day Range

MA: $6.75

$5.70

$7.80

2 Week Range

Now: $7.54

$2.85

$7.90

Volume

227,778 shs

Average Volume

379,593 shs

Market Capitalization

$383.71 million

P/E Ratio

12.36

Dividend Yield

N/A

Beta

1.19